Jazz Pharmaceuticals Plc Price Target Increased to $210.00 by Analysts at Guggenheim (JAZZ)
Equities researchers at Guggenheim boosted their price target on shares of Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) from $140.00 to $210.00 in a research report issued on Wednesday, Stock Ratings News reports. The firm currently has a “buy” rating on the stock. Guggenheim’s price target indicates a potential upside of 29.58% from the stock’s previous close.
Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) traded down 7.38% on Wednesday, hitting $162.06. The stock had a trading volume of 3,562,740 shares. Jazz Pharmaceuticals Plc has a 1-year low of $50.76 and a 1-year high of $176.60. The stock’s 50-day moving average is $154.2 and its 200-day moving average is $112.3. The company has a market cap of $9.365 billion and a P/E ratio of 29.74.
Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) last issued its quarterly earnings data on Tuesday, February 25th. The company reported $1.72 earnings per share for the quarter, missing the analysts’ consensus estimate of $1.78 by $0.06. The company had revenue of $235.80 million for the quarter, compared to the consensus estimate of $238.12 million. On average, analysts predict that Jazz Pharmaceuticals Plc will post $6.37 earnings per share for the current fiscal year.
A number of other analysts have also recently weighed in on JAZZ. Analysts at Zacks reiterated a “neutral” rating on shares of Jazz Pharmaceuticals Plc in a research note on Friday, January 24th. They now have a $167.00 price target on the stock. Finally, analysts at UBS AG raised their price target on shares of Jazz Pharmaceuticals Plc from $130.00 to $164.00 in a research note on Tuesday, January 14th. They now have a “buy” rating on the stock. Four research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. Jazz Pharmaceuticals Plc has a consensus rating of “Buy” and a consensus target price of $162.29.
Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.